Famygen Life Sci Company Profile
✉ Email this page to a colleague
What is the competitive landscape for FAMYGEN LIFE SCI
FAMYGEN LIFE SCI has one approved drug.
There are eleven US patents protecting FAMYGEN LIFE SCI drugs.
Summary for Famygen Life Sci
| US Patents: | 11 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
Drugs and US Patents for Famygen Life Sci
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Famygen Life Sci | RYZUMVI | phentolamine mesylate | SOLUTION;OPHTHALMIC | 217064-001 | Sep 25, 2023 | RX | Yes | Yes | 11,844,858 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Famygen Life Sci | RYZUMVI | phentolamine mesylate | SOLUTION;OPHTHALMIC | 217064-001 | Sep 25, 2023 | RX | Yes | Yes | 10,278,918 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Famygen Life Sci | RYZUMVI | phentolamine mesylate | SOLUTION;OPHTHALMIC | 217064-001 | Sep 25, 2023 | RX | Yes | Yes | 12,201,615 | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Famygen Life Sci Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Philippines | 12021550882 | ⤷ Start Trial |
| Japan | 2016506966 | ⤷ Start Trial |
| Japan | 2022505950 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
